Could Ivermectin and Fenbendazole Change Cancer Treatment?

Ivermectin and fenbendazole are among the most frequently discussed repurposed drugs in oncology. Patients often inquire about the potential of these medications to kill cancer cells, the efficacy of the Joe Tippens protocol, and the reasons their oncologists may not mention these options. Some patients present extensive laboratory research, while others have already obtained veterinary fenbendazole online and seek guidance regarding appropriate dosing.

This interest is understandable, as both drugs are inexpensive and off patent. Laboratory research has identified several mechanisms by which they may interfere with cancer biology. Anecdotal reports of dramatic responses circulate rapidly online, particularly when individuals attribute improvement to these medications following unsuccessful standard treatments.

However, a distinction exists between demonstrating anticancer activity in laboratory settings and proving that a drug improves survival or quality of life in humans. This critical difference is often overlooked in online discussions.

Repurposed drugs should not be dismissed solely due to their age, cost, or status outside conventional oncology. Conversely, protocols derived from social media anecdotes and animal products should not be adopted without scrutiny. The responsible approach is to critically evaluate the evidence, identify existing knowledge gaps, and incorporate any off-label therapy within a carefully monitored treatment plan.

Current research on ivermectin and fenbendazole in cancer provides legitimate scientific rationale for further investigation. However, there is insufficient reliable human evidence to classify either drug as a proven cancer treatment.

Why Are Antiparasitic Drugs Being Studied for Cancer?

Drug repurposing refers to the investigation of existing medications for new therapeutic indications. This strategy is logical because researchers possess prior knowledge of the drug’s chemistry, manufacturing processes, pharmacology, and safety profile in its approved context. Repurposing may reduce the time and cost associated with developing new treatments.

Several established cancer therapies target microtubules, metabolism, cell division, or signaling pathways. Some antiparasitic medications interact with these same biological systems. While this overlap does not imply that all antiparasitic drugs are effective against cancer, it provides a scientific rationale for investigating specific compounds.

The initial stage of research typically involves testing drugs on cancer cells in vitro. If these results are promising, studies progress to animal models. Human clinical trials are conducted only when sufficient evidence supports the investigation of dosing, safety, interactions, and clinical outcomes.

Many medications demonstrate promise in preclinical stages but ultimately fail in human trials. The concentrations effective in vitro may not be safely attainable in human tissues. Additionally, drugs that are effective in animal models may exhibit different pharmacodynamics or pharmacokinetics in humans. Potential interactions with chemotherapy, immunotherapy, anticoagulants, or hepatic metabolism must also be considered.

Preclinical evidence should serve as the basis for formulating research questions, rather than being regarded as definitive proof of clinical efficacy.

What Is Ivermectin?

Ivermectin is an antiparasitic medication with approved indications in humans. It has been instrumental in the treatment of infections such as onchocerciasis (river blindness) and strongyloidiasis. Its established safety and efficacy in humans contribute to its consideration for drug repurposing.

Laboratory and animal studies have demonstrated anticancer effects of ivermectin across multiple tumor models. Proposed mechanisms include modulation of PAK1, WNT/β-catenin signaling, mitochondrial function, autophagy, apoptosis, cancer stem-cell activity, and drug resistance. These effects have been investigated in breast, colorectal, prostate, pancreatic, ovarian, bladder, brain, and other cancer models.

While these findings are scientifically noteworthy, they do not establish that ivermectin is effective in treating these cancers in human patients.

A 2025 review concluded that, although ivermectin is supported by substantial preclinical research, conclusive evidence from human studies is lacking. This assessment accurately reflects the current state of the field. Ivermectin warrants further investigation but has not yet met the evidentiary threshold required to be considered an effective cancer therapy.

What Human Evidence Exists for Ivermectin and Cancer?

Evidence from human studies remains limited; however, research is gradually progressing beyond laboratory investigations.

A phase II study evaluated ivermectin in combination with pembrolizumab for metastatic triple-negative breast cancer. Early-stage cancer trials primarily assess safety and dosing and typically enroll small patient cohorts. Even if an experimental combination demonstrates responses, it remains necessary to determine whether ivermectin contributes additional benefit beyond immunotherapy, whether observed effects persist in larger populations, and whether the treatment improves progression-free or overall survival.

In June 2026, researchers published a prospective observational cohort study involving 197 patients prescribed ivermectin and mebendazole via a telemedicine platform. Of these patients, 122 completed a six-month follow-up period. The authors reported high rates of self-reported stable disease, regression, or absence of detectable disease.

Although the findings attracted attention, the study design does not permit causal inference. The absence of a randomized control group, the inclusion of patients with diverse cancer types, and concurrent treatments such as chemotherapy, radiation, surgery, supplements, or dietary interventions limit interpretability. Outcomes were self-reported, and over one-third of participants did not complete follow-up. The journal later published an expression of concern regarding the article.

This study is hypothesis-generating and supports the need for controlled clinical trials. It does not provide evidence that ivermectin and mebendazole caused the reported outcomes.

Currently, human evidence is insufficient to support clinical benefit or to recommend substituting ivermectin for treatments with established efficacy. However, existing activity justifies further research.

What Is Fenbendazole?

Fenbendazole is a benzimidazole antiparasitic agent utilized in veterinary medicine and is not approved by the FDA for human use. This distinction is important, as patients may consider fenbendazole, mebendazole, and albendazole interchangeable. Although these drugs belong to the same pharmacological class, they differ in regulatory status, formulation, pharmacokinetics, and available human safety data.

Mebendazole and albendazole are approved for human antiparasitic indications. In contrast, fenbendazole is manufactured and labeled exclusively for veterinary use. Products intended for animals, such as those sold for dogs, horses, or livestock, are not considered human pharmaceutical products.

Laboratory research has demonstrated that fenbendazole disrupts microtubule formation, interferes with glucose uptake, alters cell-cycle progression, and induces cancer cell death in specific models. A frequently cited 2018 study reported that fenbendazole functions as a moderate microtubule-destabilizing agent and influences multiple cellular pathways in cancer models.

These findings are preclinical. No completed randomized human trials have demonstrated that fenbendazole improves cancer survival, reduces disease progression, or prevents recurrence.

What Is the Joe Tippens Protocol?

Public interest in fenbendazole as a potential cancer treatment is closely linked to the case of Joe Tippens, who was diagnosed with small-cell lung cancer in 2016. His case is frequently portrayed as one in which he became cancer-free after using fenbendazole when conventional therapies were no longer effective. However, a review of his complete treatment history reveals a more complex scenario.

According to Tippens’ public account, chemotherapy and radiation were initiated in September 2016 to target a large tumor in his left lung and affected lymph nodes. Following the development of pneumonia, his radiation schedule was intensified to twice-daily sessions. He subsequently experienced severe radiation-induced esophageal injury, necessitating intravenous hydration due to an inability to eat for approximately eight weeks. Additionally, he received prophylactic cranial irradiation, a measure sometimes employed in small-cell lung cancer to address the risk of brain metastasis.

A PET scan conducted in January 2017 reportedly indicated that chemotherapy and radiation had controlled the original tumor in the left lung. However, new cancerous lesions were identified in the neck, right lung, stomach, liver, bladder, pancreas, and tailbone. Subsequently, Tippens enrolled in a clinical trial at MD Anderson Cancer Center, where he received pembrolizumab (Keytruda), an immune checkpoint inhibitor intended to enhance the immune system’s ability to recognize and target cancer cells.

In the third week of January 2017, while participating in the Keytruda clinical trial, Tippens began self-administering veterinary fenbendazole in combination with curcumin, vitamin E, and CBD oil. A PET scan in May 2017 reportedly demonstrated no evidence of residual, recurrent, or metastatic disease. He remained enrolled in the clinical trial until September 2017.

The sequence of treatments is significant. Tippens received chemotherapy, thoracic radiation, prophylactic cranial irradiation, and Keytruda either prior to or concurrently with fenbendazole and supplements. Fenbendazole was not administered as a standalone intervention. Furthermore, the protocol disseminated online has evolved, with subsequent versions including or omitting ingredients such as vitamin E, berberine, and ivermectin.

When multiple treatments are administered concurrently, it becomes impossible to attribute the observed outcome to a specific intervention. The response could have resulted from Keytruda, delayed effects of chemotherapy and radiation, fenbendazole, a combination of these treatments, or individual biological factors. Temporal association alone does not establish causality.

Nevertheless, individual experiences such as this can generate valuable research questions. However, a single case cannot determine response rates, optimal dosing, safety profiles, potential drug interactions, or expected outcomes for other patients.

The 'Joe Tippens protocol' does not constitute a validated cancer treatment regimen. No standardized version has undergone evaluation in randomized human clinical trials. Tippens’ experience should be characterized as a notable individual outcome involving multiple simultaneous medical and nonmedical interventions, rather than as evidence that fenbendazole was responsible for his cancer remission.

Does Fenbendazole Cure Cancer?

There is no reliable human evidence demonstrating that fenbendazole cures cancer. Assertions that it “starves” cancer, eliminates tumors, or prevents recurrence are not supported by current data.

A three-patient case series published in 2025 attracted attention for reporting favorable outcomes in individuals who self-administered fenbendazole. However, the journal retracted this paper in January 2026. A retracted case series cannot serve as evidence of effectiveness.

Even a well-documented case report cannot establish drug efficacy. Such reports lack comparison groups and cannot control for concurrent treatments, tumor biology, diagnostic uncertainty, or selection bias. Case reports are valuable for identifying signals and unexpected events, but they do not define standards of care.

A more appropriate inquiry is whether, across a defined group of comparable patients, fenbendazole improves objective outcomes compared with an appropriate control group.

This question remains unanswered.

Fenbendazole Safety Is Not Established in Humans

A prevalent and hazardous online claim is that fenbendazole is “virtually non-toxic” due to its use in animals. However, veterinary safety data cannot determine a safe dose for human cancer treatment. Factors such as dose, duration, formulation, metabolism, and species differences are critical considerations.

Published reports have associated self-administered fenbendazole with serious liver injury. For example, a 2021 report described an 80-year-old woman with advanced non-small-cell lung cancer who developed liver injury after taking fenbendazole based on social media information. Her liver function improved after discontinuation, and no tumor shrinkage attributable to fenbendazole was documented.

A separate 2024 case reported severe drug-induced liver injury following self-administration of veterinary fenbendazole. In 2026, another report described severe liver injury in a patient with prostate cancer who combined veterinary-grade fenbendazole and ivermectin.

The FDA has reported bone marrow hypoplasia and pancytopenia in dogs treated with fenbendazole for durations exceeding labeled recommendations. While animal adverse events do not precisely predict human risk, they contradict claims that prolonged use is harmless.

Elevations in AST or ALT should not be interpreted as evidence that dead cancer cells are passing through the liver. Increased liver enzymes may indicate drug-induced injury, disease progression, biliary obstruction, infection, or other serious conditions. Assuming therapeutic efficacy without proper evaluation may delay identification of a potentially dangerous reaction.

Clinical Oversight Is Required for Ivermectin Use

Although ivermectin is approved for certain human uses, this does not imply that any dose or duration is safe for cancer treatment. FDA-approved labeling for ivermectin is based on specific parasitic conditions and defined dosing schedules, not indefinite oncology protocols.

Ivermectin is primarily metabolized via CYP3A4. Drug exposure varies with food intake, and potential interactions or additive effects must be considered. Prescribing information notes rare increases in INR when ivermectin is used with warfarin. Neurologic effects, gastrointestinal symptoms, rash, dizziness, hypotension, and liver injury also warrant consideration, particularly in medically complex patients.

Veterinary ivermectin should not be used in humans. Animal formulations differ in concentration, composition, and inactive ingredients, and have not been tested or manufactured for human administration.

Cancer patients frequently use multiple prescriptions, supplements, and treatments concurrently. This increases the importance of medication reconciliation, baseline laboratory testing, and ongoing follow-up.

Should Ivermectin or Fenbendazole Replace Standard Cancer Treatment?

Neither drug has evidence supporting its use as a replacement for surgery, radiation, chemotherapy, hormone therapy, immunotherapy, or other established cancer treatments.

However, this does not imply that every conventional recommendation is appropriate for every patient. Cancer care should be individualized, with the expected benefits of treatment weighed against risks, quality of life, disease stage, tumor biology, age, comorbidities, and patient goals.

Patients should receive comprehensive discussions regarding their treatment options and be informed when evidence supporting a particular intervention is limited.

When a repurposed medication is prescribed off-label, it should be integrated into a comprehensive treatment plan. This includes a defined purpose, clear rationale, documented informed consent, appropriate sourcing, interaction review, laboratory monitoring, imaging or tumor-marker follow-up, and predetermined criteria for continuation or discontinuation.

Labeling a drug as “adjunctive” does not exempt it from the need for evidence-based judgment and monitoring. Adding an unproven drug to established therapy still requires rigorous oversight.

Key Questions to Consider Before Using a Repurposed Drug

If you are considering ivermectin, mebendazole, or another repurposed medication, consider asking the following questions:

1. Is the evidence from cell studies, animal models, case reports, observational data, or randomized human trials?
2. Has this approach been studied in my specific cancer type and stage?
3. What measurable outcome are we trying to influence?
4. How will we know whether the treatment is helping?
5. What medications or supplements could interact with it?
6. What baseline and follow-up laboratory tests are needed?
7. Is the medication made for humans and dispensed by a licensed pharmacy?
8. Could it interfere with my current cancer treatment?
9. What side effects require stopping it?
10. When will we reassess the plan?

These questions help shift the discussion from anecdotal testimonials to evidence-based clinical decision-making.

My Perspective on Ivermectin and Fenbendazole in Cancer Care

I remain interested in repurposed medications because cancer is a complex, multi-pathway disease, and many patients require options that extend beyond conventional treatment models. Ivermectin possesses sufficient preclinical evidence and human pharmacological data to warrant rigorous oncology trials. Mebendazole, a related medication approved for human use, has a more substantial clinical research foundation compared to fenbendazole.

Fenbendazole differs in several important respects. Its anticancer evidence is primarily preclinical, its safety profile in humans remains unestablished, and the use of veterinary formulations introduces additional risks. Furthermore, online protocols frequently specify precise dosages with a degree of confidence that is not supported by human evidence.

The appropriate response is neither uncritical acceptance nor outright dismissal, but rather a disciplined and systematic investigation.

Patients should not feel compelled to conceal their use of medications due to fear of ridicule, as this increases risk. Clinicians are encouraged to inquire directly about veterinary medications, online protocols, supplements, and off-label drugs. Patients should anticipate transparent discussions regarding established knowledge, existing uncertainties, and the methods by which any therapy would be monitored.

Ivermectin and fenbendazole are not established cancer cures, nor are they equivalent medications. They should not be obtained as veterinary products or used in place of individualized cancer care. The research question remains unresolved, particularly for ivermectin and human benzimidazoles. Clinical claims circulating online significantly outpace the available evidence.

If you are considering repurposed medications as part of your cancer management strategy, take time to evaluate the complete clinical context. Review the pathology, disease stage, imaging results, laboratory trends, current treatments, potential medication interactions, and personal objectives. Developing a thoughtful, individualized plan is more effective than adopting a protocol designed for another patient.

Frequently Asked Questions (FAQ)

Does ivermectin kill cancer cells?

Ivermectin has demonstrated the ability to kill or inhibit cancer cells in laboratory studies and has shown activity in animal models. However, these findings do not establish efficacy in treating cancer in humans. Clinical trials involving humans remain limited.

Is ivermectin FDA-approved for cancer?

No. Ivermectin is approved by the FDA for specific parasitic infections in humans, but it is not approved for cancer treatment.

Is fenbendazole approved for human use?

No. Fenbendazole is an antiparasitic medication intended for veterinary use. Mebendazole and albendazole are related compounds that are approved for human use, but they are distinct from fenbendazole.

Did Joe Tippens cure his cancer with fenbendazole?

Joe Tippens reported a favorable cancer outcome while using fenbendazole and other products in addition to standard medical treatment. However, his individual experience does not determine which intervention contributed to the outcome or whether the protocol is effective for others.

Is the Joe Tippens protocol scientifically proven?

No. There is no standardized Joe Tippens protocol that is supported by evidence from randomized human clinical trials.

Can ivermectin and fenbendazole be taken together?

There is no established cancer regimen demonstrating that this combination is safe or effective. A 2026 case report documented severe liver injury following the combined use of veterinary-grade fenbendazole and ivermectin.

What is the difference between fenbendazole and mebendazole?

Both fenbendazole and mebendazole are benzimidazole antiparasitic drugs. Fenbendazole is used exclusively in veterinary medicine and is not approved for human use. Mebendazole is approved for human antiparasitic indications and has more extensive human safety data, although its application in cancer treatment is off-label and remains under investigation.

About the Author

Dr. Stephen Petteruti is a board-certified physician, published researcher, medical educator, and author of Fight Cancer Like a Man. For more than 30 years, his work has focused on preventive medicine, men’s health, healthy aging, and helping patients make informed decisions about conventional, integrative, and repurposed treatment strategies.

Medical Information

This article provides general education and does not establish a physician-patient relationship. Do not start, stop, or replace cancer treatment based on online information. Veterinary medications should not be used in humans.

By Stephen Petteruti, DO
Board-Certified Physician, Published Researcher, Author of Fight Cancer Like a Man
Updated July 30, 2026

References

1. Patel Y, Chawla J, Parmar MS. Ivermectin in cancer treatment: should healthcare providers caution or explore its therapeutic potential? Curr Oncol Rep. Published online July 26, 2025. PubMed
2. Juarez M, Schcolnik-Cabrera A, Dominguez-Gomez G, et al. Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug. Cancer Chemother Pharmacol. 2020;85:1153-1163. PubMed
3. ClinicalTrials.gov. Ivermectin in combination with balstilimab in metastatic triple-negative breast cancer. NCT05318469. ClinicalTrials.gov
4. Hulscher N, Victory K, Thorp JA, et al. Real-world clinical outcomes of ivermectin and mebendazole in cancer patients: results from a prospective observational cohort. Anticancer Res. 2026;46(6):3243-3255. Expression of concern published June 9, 2026. PubMed
5. Dogra N, Kumar A, Mukhopadhyay T. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Sci Rep. 2018;8:11926. Scientific Reports
6. Yamaguchi T, Shimizu J, Oya Y, Horio Y, Hida T. Drug-induced liver injury in a patient with nonsmall cell lung cancer after the self-administration of fenbendazole based on social media information. Case Rep Oncol. 2021;14(2):886-891. PubMed Central
7. Thakurdesai A, et al. Severe drug-induced liver injury due to self-administration of the veterinary anthelmintic medication fenbendazole. ACG Case Rep J. 2024;11(5). Journal article
8. Powderly GE, et al. Drug-induced liver injury following co-ingestion of veterinary-grade fenbendazole and ivermectin in a patient with prostate cancer. Published online 2026. PubMed
9. US Food and Drug Administration. Dear Veterinarian Letter regarding adverse events associated with extra-label use of fenbendazole in dogs. April 8, 2024. FDA
10. US Food and Drug Administration. Stromectol (ivermectin) prescribing information. FDA prescribing information
11. Karger Publishers. Retraction statement: fenbendazole as an anticancer agent? January 21, 2026. Retraction statement